Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Getting together for GPCRs
August 2019
SHARING OPTIONS:

GHENT, Belgium & DRESDEN, Germany—A new drug discovery collaboration is underway between Confo Therapeutics and DyNAbind GmbH, centered on an undisclosed G-protein coupled receptor (GPCR). Per the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates that result from this deal, and will assume responsibility for the development, manufacture and commercialization of such candidates. The companies will combine ConfoBody-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library to discover small-molecule GPCR-modulating compounds.
 
“This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project,” commented Dr. Christel Menet, Confo Therapeutics’ chief scientific officer.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.